Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
J Med Microbiol ; 60(Pt 7): 1038-1042, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21393451

ABSTRACT

Erythrasma is a superficial skin disease caused by Gram-positive Corynebacterium species. Coral-red fluorescence under Wood's light, strongly suggestive of erythrasma, can be attributed to the presence of porphyrins. Fractionated porphyrin analysis in erythrasma lesions is yet to be reported. We attempted to investigate erythrasma lesions by isolating the responsible bacteria and determining their exogenous porphyrin production by HPLC analysis. We observed a 78-year-old woman with erythrasma who had a well-demarcated slightly scaling patch on her left foot, between the fourth and fifth toes. Two kinds of colonies on 5 % sheep blood agar were obtained from this lesion. Analysis of the 16S rRNA sequence revealed the colonies to be Corynebacterium aurimucosum and Microbacterium oxydans. HPLC analysis demonstrated that coproporphyrin III (Copro III) levels were clearly elevated, although the amounts of protoporphyrin were diminished. These results indicate that the fluorescent substance was Copro III. This study supports the view that excess Copro III synthesis by C. aurimucosum and M. oxydans leads to accumulation of porphyrin in cutaneous tissue, which emits a coral-red fluorescence when exposed to Wood's light.


Subject(s)
Actinomycetales/metabolism , Coproporphyrins/biosynthesis , Erythrasma/microbiology , Aged , Corynebacterium/metabolism , Erythrasma/pathology , Female , Gene Expression Regulation, Bacterial/physiology , Humans
2.
Cancer Genet Cytogenet ; 201(1): 6-14, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20633762

ABSTRACT

Unlike the case with some other solid tumors, whole genome array screening has not revealed prognostic genetic aberrations in primary gastric cancer. Comparative genomic hybridization (CGH) using bacterial artificial chromosome (BAC) arrays for 56 primary gastric cancers resulted in identification of four prognostic loci in this study: 6q21 (harboring FOXO3A; previously FKHRL1), 9q32 (UGCG), 17q21.1 approximately q21.2 (CASC3), and 17q21.32 (HOXB3 through HOXB9). If any one of these four loci was deleted, the prognosis of the patient was significantly worse (P = 0.0019). This was true even for advanced tumors (stage IIIA, IIB, or IV, n = 39) (P = 0.0113), whereas only 1 of the 17 patients with less advanced tumors (stage IA, IB, or II; n = 17) died of disease after surgery. Multivariate analysis according to the status of four BACs or pathological stage based on the Japanese Classification of Gastric Carcinoma (stages IA, IB, and II vs. stages IIIA, IIIB, and IV) demonstrated that the BAC clone status was also an independent prognostic factor (P = 0.006). These findings may help predict which patients with malignant potential need more intensive therapy, or may point to new therapeutic approaches especially for advanced tumors. The parameter here termed the integrated genomic prognostic biomarker may therefore be of clinical utility as a prognostic biomarker.


Subject(s)
Biomarkers, Tumor/genetics , Genome, Human , Nucleic Acid Hybridization , Stomach Neoplasms/genetics , Base Sequence , Chromosome Mapping , Chromosomes, Artificial, Bacterial , DNA Primers , Humans , Polymerase Chain Reaction , Prognosis
3.
PLoS One ; 3(8): e3070, 2008 Aug 27.
Article in English | MEDLINE | ID: mdl-18728780

ABSTRACT

Haem is a prosthetic group for haem proteins, which play an essential role in oxygen transport, respiration, signal transduction, and detoxification. In haem biosynthesis, the haem precursor protoporphyrin IX (PP IX) must be accumulated into the mitochondrial matrix across the inner membrane, but its mechanism is largely unclear. Here we show that adenine nucleotide translocator (ANT), the inner membrane transporter, contributes to haem biosynthesis by facilitating mitochondrial accumulation of its precursors. We identified that haem and PP IX specifically bind to ANT. Mitochondrial uptake of PP IX was inhibited by ADP, a known substrate of ANT. Conversely, ADP uptake into mitochondria was competitively inhibited by haem and its precursors, suggesting that haem-related porphyrins are accumulated into mitochondria via ANT. Furthermore, disruption of the ANT genes in yeast resulted in a reduction of haem biosynthesis by blocking the translocation of haem precursors into the matrix. Our results represent a new model that ANT plays a crucial role in haem biosynthesis by facilitating accumulation of its precursors into the mitochondrial matrix.


Subject(s)
Mitochondria, Liver/enzymology , Mitochondrial ADP, ATP Translocases/metabolism , Animals , Heme/chemistry , Heme/metabolism , Hemeproteins/metabolism , Kinetics , Mitochondrial ADP, ATP Translocases/chemistry , Models, Molecular , Molecular Weight , Protein Conformation , Protoporphyrins/metabolism , Rats
4.
Nihon Eiseigaku Zasshi ; 63(3): 628-35, 2008 May.
Article in Japanese | MEDLINE | ID: mdl-18567368

ABSTRACT

UNLABELLED: We sought to establish a causal relationship between oxidative stress and porphyria in patients and carriers. We reported changes in urinary porphyrin concentrations related to 8-hydroxy-2'-deoxyguanosine. METHODS: We measured urinary 8-hydroxy-2'-deoxyguanosine concentration in porphyria patients and carriers with multifactorial inheritance as a possible marker of attack. The porphyria types included 10 patients with porphyria cutanea tarda, 5 with variegate porphyria, 8 with hereditary coproporphyria, 7 with congenital erythropoietic porphyria, 5 with erythropoietic protoporphyria, 5 with acute intermittent porphyria, 7 erythropoietic protoporphyria carriers, and 7 acute intermittent porphyria carriers. RESULTS: Urinary porphyrin concentrations in these patients were significantly higher than those in healthy subjects (p<0.001). Urinary 8-hydroxy-2'-deoxyguanosine concentrations were significantly high in dermatopathy porphyria types namely porphyria cutanea tarda (p<0.001), variegate porphyria (p<0.05), hereditary coproporphyria (p<0.05), congenital erythropoietic phyria (p<0.05), and erythropoietic protoporphyria (p<0.001). CONCLUSION: These results reveal that urinary 8-hydroxy-2'-deoxyguanosine concentration in cutis porphyria types is a good predictor of attack and abatement.


Subject(s)
Carrier State/diagnosis , Deoxyguanosine/analogs & derivatives , Oxidative Stress/physiology , Porphyrias/diagnosis , Porphyrias/etiology , 8-Hydroxy-2'-Deoxyguanosine , Biomarkers/urine , Carrier State/classification , Deoxyguanosine/urine , Humans , Porphyria Cutanea Tarda/diagnosis , Porphyria, Variegate/diagnosis , Porphyrias/classification
5.
Surg Today ; 37(6): 474-81, 2007.
Article in English | MEDLINE | ID: mdl-17522764

ABSTRACT

PURPOSE: The antitumor effects of Interferon-beta (IFN-beta) are due to its direct inhibition of cell proliferation, immunostimulatory activity, and the inhibition of angiogenesis. We investigated the mechanism of the effects of IFN-beta on a murine colon 26 cell line (CT 26) and its highly metastatic variant (L5). METHODS: We examined its inhibitory effects on cell proliferation in vitro and the development of liver metastases in vivo. RESULTS: The proliferation of CT 26 in vitro was inhibited by IFN-beta in a dose- and time-dependent manner. The number of metastases was reduced in mice inoculated with CT 26 (P<0.01) and L5 (P<0.01) on Day 14 after treatment with IFN-beta. The median survival rate of the mice inoculated with L5 administered IFN-beta every other day, or every day was higher than in the control group (P<0.05). A dorsal air sac assay demonstrated that IFN-beta inhibited angiogenesis in mice inoculated with CT 26, but the effects disappeared with aminoguanidine, an inducible nitric oxide synthase inhibitor. CONCLUSION: These results showed that IFN-beta directly inhibits the proliferation of CT 26. In addition, the in vivo experiments suggested that IFN-beta might effectively inhibit liver metastases.


Subject(s)
Antineoplastic Agents/therapeutic use , Interferon Type I/therapeutic use , Liver Neoplasms, Experimental/drug therapy , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Female , Interferon Type I/pharmacology , Mice , Mice, Inbred BALB C , Recombinant Proteins
6.
Gan To Kagaku Ryoho ; 34(4): 563-7, 2007 Apr.
Article in Japanese | MEDLINE | ID: mdl-17431342

ABSTRACT

A dose-escalation study was conducted for postoperative patients with stage IV gastric cancer to determine the recommended dose of daily intravenous cisplatin combined with a fixed dose of TS-1. TS-1 was administered orally twice daily for 2 weeks followed by a 1-week rest. The dose of TS-1 was based on the body surface area (BSA) as follows: 80 mg/day for BSA less than 1.25, 100 mg/day for BSA 1.25 to less than 1.50, and 120 mg/day for BSA 1.5 or more. Three dose levels of cisplatin (2, 4, 6 mg/m(2)) were studied, and two courses were performed. Cisplatin was infused on day 1-5 and 8-12 for 30 minutes. The National Cancer Institute common toxicity criteria (NCI-CTC Version 3) were used to evaluate the grade of toxicity. Three patients enrolled in each level. Dose escalation was performed when dose-limiting toxicities (DLT) were seen in 0/3, and 3 more cases of the same level were added when DLTs were seen 1-2/3. Maximum-tolerated dose (MTD) were determined when DLTs were seen in 3 cases. DLTs were not recorded during the administration of CDDP up to 4 mg/m(2). However, DLTs were seen 3/3 at level 3. From these results, cisplatin of 4 mg/m(2)was determined to be the recommended dose (RD) in this protocol for postoperative stage IV gastric carcinoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Stomach Neoplasms/drug therapy , Administration, Oral , Aged , Cisplatin/administration & dosage , Cisplatin/blood , Drug Administration Schedule , Drug Combinations , Female , Gastrectomy , Humans , Male , Maximum Tolerated Dose , Middle Aged , Neoplasm Staging , Oxonic Acid/administration & dosage , Oxonic Acid/blood , Postoperative Period , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tegafur/administration & dosage , Tegafur/blood
7.
Int J Mol Med ; 16(1): 119-26, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15942688

ABSTRACT

Macrophage migration inhibitory factor (MIF) is known to play an important role in broad-spectrum inflammation and immune responses. To evaluate the role of MIF in tumor growth, we established transgenic (Tg) mice (ICR strain) driven by cytomegalovirus (CMV) enhancer and beta-actin promoter. We inoculated Tg mice in the back with murine sarcoma cell line S-180 cells. The tumor growth rate was more enhanced in Tg mice than in littermate non-Tg mice up to day 9 after tumor inoculation. Surprisingly, most tumors embedded on the back of Tg mice regressed at day 10 after inoculation and eventually disappeared. Tumor volumes of non-Tg mice incessantly increased until death. We reinoculated the Tg mice with S-180 cells, which had been recovered from the first challenge, and found that the tumor cells were completely rejected in all cases. To identify the effector cells that eradicated the tumor cells, we prepared spleen cells from tumor-bearing Tg mice and carried out cell lysis assay. The magnitude of cytolytic activity of spleen cells obtained from Tg mice was significantly higher against S-180 cells, as well as natural killer cell-sensitive YAC-1 cells, than was the activity of cells from non-Tg mice. Furthermore, we observed that CTL activity of Tg mice against S-180 cells was significantly decreased by the deletion of CD8+ T cells or NK cells. On the other hand, the deletion of CD4+ cells minimally affected the cytolytic activity. Taken together, these results suggest that MIF has the potential to promote tumor growth and angiogenesis in the early phase and, by contrast, this protein could activate CD8+ cytotoxic T cells and NK cells, leading to tumor regression.


Subject(s)
Macrophage Migration-Inhibitory Factors/metabolism , Sarcoma/metabolism , Sarcoma/pathology , Animals , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/metabolism , Cell Line, Tumor , Disease Progression , Female , Immunohistochemistry , Killer Cells, Natural/cytology , Lymphocyte Count , Macrophage Migration-Inhibitory Factors/genetics , Mice , Mice, Inbred ICR , Mice, Transgenic , Promoter Regions, Genetic/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sarcoma/blood supply , Sarcoma/genetics , Spleen/cytology , T-Lymphocytes, Cytotoxic/cytology
8.
Gan To Kagaku Ryoho ; 32(3): 381-4, 2005 Mar.
Article in Japanese | MEDLINE | ID: mdl-15791822

ABSTRACT

In the present study, we demonstrate the result of low-dose FP treatment as an adjuvant therapy for 30 patients of stage II or more progressive gastric cancer. 5-FU and CDDP were injected intravenously for 10 days from day 1 through day 5, and day 8 through 12 for 2 weeks at a dose of 250 mg/body and 10 mg/body, or for 14 days at a dose of 250 mg/m2/day and 5 mg/m2/day, respectively. Patients were excluded if they received less than 80% of the respective doses in a course of treatment by the protocol. This constituted a course of chemotherapy, which was repeated every 4 weeks. Grade 3 neutropenia was observed in one case. Other toxicities were anorexia, nausea, weight loss, diarrhea, general fatigue and elevation of serum creatinine, but they were not so severe. The two-year survival rate was 100% in cur A cases, 85% in cur B, and 0% in cur C. The median survival time of the cur C patients was 10 months. These results indicate that low-dose FP therapy is safe and recommendable for cur A and cur B patients. However, other treatment methods such as sequential chemotherapy are needed for cur C gastric cancer patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Stomach Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Fluorouracil/administration & dosage , Gastrectomy , Humans , Injections, Intravenous , Male , Middle Aged , Stomach Neoplasms/mortality , Stomach Neoplasms/surgery , Survival Rate
9.
Clin Cancer Res ; 11(3): 1050-8, 2005 Feb 01.
Article in English | MEDLINE | ID: mdl-15709171

ABSTRACT

PURPOSE: Macrophage migration inhibitory factor (MIF) plays an important role not only in the immune system but also in tumorigenesis. In this study, we investigated the potential role of MIF in association with tumor invasion and metastasis. METHODS: To assess the function of MIF, we knocked down the MIF mRNA using small interfering RNA (siRNA). Twenty-one base siRNA specific for the mRNA sequence of mouse MIF was introduced to a murine colon cancer cell line, colon 26. Tumor cell invasion was evaluated using a transwell method (8-microm pores) coated with Matrigel on the upperside membrane and with fibronectin on the underside membrane. Moreover, we investigated the signal transduction of lysophosphatidic acid (LPA) relevant to the Rho-dependent pathway and further examined the effect of MIF siRNA on this signal transduction system. In vivo, the tumor cells were pretreated with MIF siRNA and injected into the portal vein, and the effects on metastasis to the liver were evaluated. RESULTS: We found that MIF siRNA markedly reduced the invasion of the cells from the upperside to lowerside membranes. We revealed that the Rho-dependent pathway activated by LPA was suppressed by MIF siRNA. Next, we found that the tyrosine-phosphorylation of focal adhesion kinase and LPA-induced expressions of integrin beta1 were significantly suppressed by MIF siRNA. In vivo, metastasis to the liver was significantly inhibited by pretreatment of the cells with MIF siRNA. CONCLUSION: Taken together, these results suggest that MIF promotes tumor invasion and metastasis via the Rho-dependent pathway.


Subject(s)
Macrophage Migration-Inhibitory Factors/metabolism , Protein Serine-Threonine Kinases/metabolism , Signal Transduction , rho GTP-Binding Proteins/metabolism , Animals , Blotting, Western , Cell Line, Tumor , Female , Intracellular Signaling Peptides and Proteins , Lysophospholipids/metabolism , Macrophage Migration-Inhibitory Factors/genetics , Mice , Mice, Inbred BALB C , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Transplantation , Neoplasms, Experimental/genetics , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , RNA Interference/physiology , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , rho-Associated Kinases
10.
Rinsho Ketsueki ; 45(7): 562-7, 2004 Jul.
Article in Japanese | MEDLINE | ID: mdl-15359917

ABSTRACT

A 62-year-old man who had twice received laparotomies for abdominal pain of unknown origin was admitted to our hospital with acute abdominal pain. His family history of acute intermittent porphyria (AIP) suggested that it arose from acute porphyria. We treated the patient with 5% glucose solution by i.v. drip infusion and his abdominal pain improved rapidly. Diagnosis of AIP was established by the demonstration of reduced erythrocyte porphobilinogen deaminase (PBGD) activity and a point mutation (CAG --> CGG) in a splicing site in intron 10/exon 11 in the PBGD gene by DNA analysis. For screening of AIP carriers in his family, we measured erythrocyte PBGD activity. Four of his seven children were successfully diagnosed as AIP carriers. This is the ninth AIP family report, in which a mutation in the PBGD gene was revealed by DNA analysis.


Subject(s)
Porphyria, Acute Intermittent/genetics , Abdominal Pain/drug therapy , Abdominal Pain/etiology , Biomarkers/blood , Cimetidine/administration & dosage , Exons/genetics , Genetic Carrier Screening/methods , Glucose/administration & dosage , Humans , Hydroxymethylbilane Synthase/blood , Hydroxymethylbilane Synthase/genetics , Infusions, Intravenous , Introns/genetics , Male , Middle Aged , Point Mutation , Porphyria, Acute Intermittent/diagnosis , Porphyria, Acute Intermittent/drug therapy , RNA Splice Sites/genetics , Sequence Analysis, DNA
11.
J Immunother ; 27(5): 394-7, 2004.
Article in English | MEDLINE | ID: mdl-15314548

ABSTRACT

The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or group B. Group A patients received 800 mg/d 5'-DFUR (Furtulon) for 2 years from 2 weeks after the operation. Group B patients received OK-432 plus 5'-DFUR by the same regimen as in group A. This study enrolled 288 patients, and 1 patient with malignant lymphoma was excluded. Among the remaining 287 patients, 143 and 144 were allocated to group A and group B, respectively, and their data were included in statistical analysis. The 5-year survival rates for groups A and B were 62.9% and 63.8%, respectively, showing no significant difference (P = 0.7996).


Subject(s)
Antineoplastic Agents/therapeutic use , Immunotherapy , Picibanil/therapeutic use , Stomach Neoplasms/drug therapy , Adult , Aged , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Female , Floxuridine/therapeutic use , Humans , Male , Middle Aged , Stomach Neoplasms/mortality , Survival Analysis
12.
Int J Hematol ; 79(5): 448-56, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15239394

ABSTRACT

The first case of porphyria on record in Japan was a patient with congenital erythropoietic porphyria (CEP) reported by Sato and Takahashi in 1920. Since then until the end of December 2002, 827 cases of porphyrias have been diagnosed from characteristic clinical and/or laboratory findings (463 males, 358 females, and 6 of unknown sex). Essentially all inherited porphyrias have been found in Japan, with the incidences and clinical symptoms generally being similar to those reported for other countries. The male-female ratio was approximately 1:1 for CEP, whereas it was higher for erythropoietic protoporphyria. In contrast, preponderances of female patients exist with acute hepatic porphyrias, such as acute intermittent porphyria (AIP), variegate porphyria (VP), and hereditary coproporphyria (HCP), and with undefined acute porphyria. Although porphyria cutanea tarda (PCT) is believed to be increasing recently in women in other countries because of smoking and the use of contraceptives, it is still by far more prominent in males in Japan than in females. The recent increasing contribution of hepatitis C virus infection to PCT in Japan has also been recognized. but there have been no PCT cases in Japan with HFE gene mutations. Familial occurrence and consanguinity were high for CEP, as expected; however, significant consanguinity was also noted in families where CEP, AIP, HCP, VP, or PCT occurred as a single isolated case without a family history of disease. This survey also revealed that as many as 71% of acute hepatic porphyria cases were initially diagnosed as nonporphyria and later revised or corrected to porphyria, indicating the difficulty of diagnosing porphyria in the absence of specific laboratory testing for porphyrins and their precursors in urine, stool, plasma, and erythrocyte samples.


Subject(s)
Porphyrias/pathology , Adolescent , Adult , Aged , Child , Child, Preschool , Consanguinity , DNA Mutational Analysis , Data Collection , Female , History, 20th Century , Humans , Incidence , Infant , Infant, Newborn , Japan , Male , Middle Aged , Pedigree , Porphyrias/genetics , Porphyrias/history , Porphyrias, Hepatic , Sex Factors
13.
Article in English | MEDLINE | ID: mdl-15030143

ABSTRACT

An experiment of anaerobic filtration using a floating media was carried out in this study. In the present system, a bench-scale column of 50 mm in diameter and of 1500 mm in height and a floating media consisting of S-shaped polystyrene pieces were employed. The purpose of this study was to collect the basic data of anaerobic biological filtration using a floating media. Under the laboratory conditions, it was found that the start-up of an anaerobic biological filter took about half month at 20 degrees C and a lower BOD loading was favorable for this start-up. The BOD removal efficiency over 60% could be achieved at a BOD volumetric loading of the filter bed under 6 kg/m3/d. An effluent BOD concentration became high when the flow rate was high, especially with circulation of treated water, which afforded a large effect on an effluent BOD concentration. As for the mechanism of BOD removal by anaerobic filtration, it was evident that long retention time worked in favor for organic acid generation, and the circulation of treated water promoted decomposition of organic acids.


Subject(s)
Polystyrenes/isolation & purification , Water Pollutants/isolation & purification , Water Purification/methods , Bacteria, Anaerobic , Biodegradation, Environmental , Filtration , Particle Size
14.
Gan To Kagaku Ryoho ; 31(1): 45-9, 2004 Jan.
Article in Japanese | MEDLINE | ID: mdl-14750320

ABSTRACT

Advanced thoracic esophageal cancer has a poor prognosis despite advances in surgery, such as three-field lymph node dissection. Multimodal therapy is needed to improve local control, resectability and survival rate. Fifteen patients with advanced squamous cell carcinoma of the thoracic esophagus were treated with neoadjuvant chemoradiotherapy (NAC) combined with concurrent radiation (30 Gy/12 f) and 3 courses of 5-FU and CDDP (CDDP 5 mg/m2/day + 5-FU 250 mg/m2/day: day 1-5: div). In the absence of unresectable disease and surgical risk, 12 patients underwent esophagectomy (Group 1) and 3 patients underwent additional chemoradiotherapy because of high surgical risk (Group 2). Side effects consisted of nausea, vomiting and myelo-suppression in 8 patients, but all patients tolerated and completed a full course of NAC. The effective rate (CR + PR) of NAC was 58.3% in Group 1 and 66.7% in Group 2. No patients showed pathological CR. Two-year survival rate was 28.1% in Group 1 (PR: 33.3%, NC: 20.0%) and 33.5% in Group 2. This protocol had acceptable toxicities but did not show survival benefit. Further trials are necessary to improve survival rate.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/radiotherapy , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/surgery , Cisplatin/administration & dosage , Drug Administration Schedule , Esophageal Neoplasms/mortality , Esophageal Neoplasms/surgery , Esophagectomy , Female , Fluorouracil/administration & dosage , Humans , Lymph Node Excision , Male , Middle Aged , Neoadjuvant Therapy , Survival Rate
15.
Nihon Rinsho ; 62 Suppl 11: 707-10, 2004 Nov.
Article in Japanese | MEDLINE | ID: mdl-15628516
16.
Nihon Rinsho ; 62 Suppl 11: 715-8, 2004 Nov.
Article in Japanese | MEDLINE | ID: mdl-15628518
17.
Nihon Rinsho ; 62 Suppl 11: 722-4, 2004 Nov.
Article in Japanese | MEDLINE | ID: mdl-15628520
18.
Nihon Rinsho ; 62 Suppl 11: 725-7, 2004 Nov.
Article in Japanese | MEDLINE | ID: mdl-15628521
19.
Nihon Rinsho ; 62 Suppl 11: 728-30, 2004 Nov.
Article in Japanese | MEDLINE | ID: mdl-15628522
20.
Nihon Rinsho ; 62 Suppl 11: 731-4, 2004 Nov.
Article in Japanese | MEDLINE | ID: mdl-15628523
SELECTION OF CITATIONS
SEARCH DETAIL
...